Brokerages expect that BioTime, Inc. (NASDAQ:BTX) will report ($0.07) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for BioTime’s earnings. The lowest EPS estimate is ($0.08) and the highest is ($0.05). BioTime reported earnings per share of ($0.09) in the same quarter last year, which would suggest a positive year-over-year growth rate of 22.2%. The firm is expected to announce its next earnings report on Thursday, May 9th.
On average, analysts expect that BioTime will report full-year earnings of ($0.24) per share for the current fiscal year, with EPS estimates ranging from ($0.32) to ($0.13). For the next year, analysts forecast that the firm will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.33) to ($0.08). Zacks’ earnings per share averages are an average based on a survey of analysts that cover BioTime.
BioTime (NASDAQ:BTX) last posted its earnings results on Thursday, March 14th. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.74 million.
Several equities research analysts have recently commented on BTX shares. Dawson James reissued a “buy” rating on shares of BioTime in a research report on Thursday, February 7th. HC Wainwright reissued a “buy” rating on shares of BioTime in a research report on Thursday, February 21st.
Shares of NASDAQ:BTX traded down $0.03 during midday trading on Monday, hitting $1.22. 2,120 shares of the company’s stock were exchanged, compared to its average volume of 948,594. BioTime has a 12 month low of $0.66 and a 12 month high of $2.81.
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.
Read More: QQQ ETF
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.